Skip to Main Content

In a boost for Sarepta Therapeutics (SRPT), the last remaining large health insurer has agreed to cover its pricey treatment for a rare form of muscular dystrophy.

In a policy bulletin issued on Thursday, Anthem (ANTM) declared Exondys 51 to be “medically necessary,” reversing a decision made a year ago not to reimburse the drug, which had just been approved to treat Duchenne muscular dystrophy amid controversy about underlying clinical data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • My son Shivam Anjay age 19 years patient of DMD needs treatment by sarepta Exondys 51, when this medicine will be available in India or if I want to get treatment at USA what cost I have to bear, pl help and guide me.

Comments are closed.